Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Promising efficacy with adavosertib in uterine serous carcinoma

Publish date:: April 3, 2020

Key clinical point: Adavosertib monotherapy showed efficacy against recurrent uterine serous carcinoma.

Major finding: The overall response rate was 30% among 21 patients for whom data were available.

Study details: An interim analysis of data on 21 of 35 planned patients in a phase 2 trial.

Disclosures: Dr. Liu disclosed ties with AstraZeneca, which supported the trial, as well as Merck and other companies.

Citation:

Liu JF et al. SGO 2020, Abstract 7.

This Week's Must Reads

Higher dose maximizes effects of magnesium sulfate for obese women,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

One in five gestational carriers do not meet ASRM criteria,

Must Reads in Gynecologic Cancer

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

Is diagnostic hysteroscopy safe in patients with type 2 endometrial cancer?,

Cervical cancer recurrence patterns differ after laparoscopic and open hysterectomy,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Half of women treated for gynecologic cancers miss or skip doses of oral drugs,